Abstract
The interaction of hepcidin (HEPC) and ferroportin (FPN) is an essential event in iron homeostasis. HEPC binds to FPN, and subsequently degrades it through phosphorylation and ubiquitination. Present work described a computational study to identify interfacial residues involved in FPN–HEPC interactions. We have predicted three-dimensional structure of human FPN using homology modeling followed by docking analysis and molecular dynamics simulations. Our study revealed that FPN has HEPC-binding sites on extracellular loops: ECL4, ECL5 and ECL6. The provided outcome is consistent with mutagenesis studies on FPN. We have identified several electrostatic interactions between charged residues Asp325 (ECL4), ECL5 (Glu448) and Glu518 (ECL6) of FPN with residues His3, Arg16, Lys18 of HEPC, which are essentially important for interfacial contact between them. These results provide an evidence for structural basis of FPN–HEPC interactions and their future clinical application.
Keywords: Ferroportin, Hepcidin, Structural modulation, Elastic network model, Iron homeostasis.
Letters in Drug Design & Discovery
Title:Identification of Interfacial Residues Involved in Hepcidin-Ferroportin Interaction
Volume: 11 Issue: 3
Author(s): Prasoon Kumar Thakur, Amresh Prakash, Parvez Khan, Robert E. Fleming, Abdul Waheed, Faizan Ahmad and Md. Imtaiyaz Hassan
Affiliation:
Keywords: Ferroportin, Hepcidin, Structural modulation, Elastic network model, Iron homeostasis.
Abstract: The interaction of hepcidin (HEPC) and ferroportin (FPN) is an essential event in iron homeostasis. HEPC binds to FPN, and subsequently degrades it through phosphorylation and ubiquitination. Present work described a computational study to identify interfacial residues involved in FPN–HEPC interactions. We have predicted three-dimensional structure of human FPN using homology modeling followed by docking analysis and molecular dynamics simulations. Our study revealed that FPN has HEPC-binding sites on extracellular loops: ECL4, ECL5 and ECL6. The provided outcome is consistent with mutagenesis studies on FPN. We have identified several electrostatic interactions between charged residues Asp325 (ECL4), ECL5 (Glu448) and Glu518 (ECL6) of FPN with residues His3, Arg16, Lys18 of HEPC, which are essentially important for interfacial contact between them. These results provide an evidence for structural basis of FPN–HEPC interactions and their future clinical application.
Export Options
About this article
Cite this article as:
Thakur Kumar Prasoon, Prakash Amresh, Khan Parvez, Fleming E. Robert, Waheed Abdul, Ahmad Faizan and Hassan Imtaiyaz Md., Identification of Interfacial Residues Involved in Hepcidin-Ferroportin Interaction, Letters in Drug Design & Discovery 2014; 11 (3) . https://dx.doi.org/10.2174/15701808113106660088
DOI https://dx.doi.org/10.2174/15701808113106660088 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Cellular Biomolecules in Screening, Diagnosis and Treatment of Colorectal Cancer
Current Drug Metabolism Optical Coherence Tomography Detection of Neurodegeneration in Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Human UDP-Glucuronosyltransferase 2B7
Current Drug Metabolism TGF-β Signaling in Gastrointestinal Cancer Stem Cells
Current Cancer Therapy Reviews Chemically Functionalized Carbon Nanotubes: Emerging Vectors for Cell Therapy
Mini-Reviews in Medicinal Chemistry Viral Encephalitis: Current Treatments and Future Perspectives
Central Nervous System Agents in Medicinal Chemistry Controversies in the Use of Nutritional Supplements in Ophthalmology
Current Pharmaceutical Design Anti-IL-12/23 in Crohn's Disease: Bench and Bedside
Current Drug Targets Micro RNA: An Epigenetic Regulator of Type 2 Diabetes
MicroRNA Stem-cell-based Therapies for Improving Islet Transplantation Outcomes in Type 1 Diabetes
Current Diabetes Reviews Hereditary Haemorrhagic Telangiectasia (HHT): Genetic and Molecular Aspects
Current Pharmaceutical Design A Murine Model of Vasculitis Induced by Fungal Polysaccharide
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting Angiogenesis for Treatment of NSCLC Brain Metastases
Current Cancer Drug Targets Immunological Disturbances and Neuroimaging Findings in Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD) Comorbid Patients
Current Topics in Medicinal Chemistry Pharmacological Uses of the Plants Belonging to the Genus <i>Commiphora</i>
Cardiovascular & Hematological Agents in Medicinal Chemistry Potential Targets for Improving Radiosensitivity of Breast Tumor-Initiating Cells
Anti-Cancer Agents in Medicinal Chemistry Targeting the Nogo Receptor Complex in Diseases of the Central Nervous System
Current Medicinal Chemistry Physical Exercise in MCI Elderly Promotes Reduction of Pro-Inflammatory Cytokines and Improvements on Cognition and BDNF Peripheral Levels
Current Alzheimer Research Biological Abilities of Rice Bran-Derived Antioxidant Phytochemicals for Medical Therapy
Current Topics in Medicinal Chemistry Clinical Efficacy and Effectiveness of Ursodeoxycholic Acid in Cholestatic Liver Diseases
Current Clinical Pharmacology